An Efficient Orchestration Engine for the Cloud

The Cloud is evolving as a cost-effective solution to run services that support a variety of business processes. It is not surprising then that Orchestration as a Service (OaaS) is gaining importance as a means to integrate the many services a typical company runs or outsources in the Cloud. OaaS requires very efficient orchestration engines: the faster they work, the less customers have to pay and the more customers can be served. In this paper, we report on a new orchestration engine; we have performed a series of stringent experiments that prove that it outperforms a state-of-the-art orchestration engine in widespread use. Our conclusion is that our proposal is an efficient, solid orchestration engine ready for the Cloud.Ministerio de Educación y Ciencia TIN2007-64119Junta de Andalucía P07-TIC-2602Junta de Andalucía P08-TIC-4100Ministerio de Ciencia e Innovación TIN2008- 04718-EMinisterio de Ciencia e Innovación TIN2010-21744Ministerio de Economía, Industria y Competitividad TIN2010-09809-EMinisterio de Ciencia e Innovación TIN2010-10811-EMinisterio de Ciencia e Innovación TIN2010-09988-

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.

BACKGROUND: A randomized Phase II study evaluated the activity of weekly paclitaxel versus its combination with trastuzumab for treatment of patients with advanced breast cancer overexpressing HER-2. PATIENTS AND METHODS: Among 124 patients randomized, 123 are assessable for toxicity and 118 for response. Patients received weekly paclitaxel single agent (80 mg/m2) or combined with trastuzumab (4 mg/kg loading dose, then weekly 2 mg/kg). HER-2 overexpression was determined by immunohistochemistry (IHC). Patients with 2+/3+ IHC scores were eligible. IHC was compared with HER-2 serum extracellular domain (ECD). RESULTS: Patient characteristics were similar in the two arms. Both treatments were feasible and well tolerated with no grade 4 hematologic toxicity. No patient developed cardiac toxicity. The combined treatment was statistically significant superior for overall response rate (ORR) (75% vs. 56.9%; P = 0.037), particularly in the subset of IHC 3+ patients (84.5% vs. 47.5%; P = 0.00050). A statistically significant better median time to progression was seen in the subgroup with IHC 3+ (369 vs. 272 days; P = 0.030) and visceral disease (301 vs. 183 days; P = 0.0080) treated with combination. Multivariable analysis of predictive factors showed that only IHC score retained statistically significant value for ORR (P = 0.0035). CONCLUSION: Weekly paclitaxel plus trastuzumab is highly active and safe and it is superior to paclitaxel alone in patients with IHC score of 3+

Uma solução m-Health para apoio à educação em saúde com foco na mudança de comportamento para hábitos saudáveis

Este artigo apresenta uma solução m-Health para apoio à educação em saúde constituída por um aplicativo para Android no dispositivo móvel cliente e uma aplicação em máquina servidora. Diferentes conceitos e teorias estão integrados visando aumentar a motivação do usuário, com foco na mudança de comportamento para hábitos mais saudáveis e melhoria da qualidade de vida. Uma avaliação da interface da aplicação foi realizada através de questionário baseado na ISO 9241-11 e ABNT ISO/IEC 25062:2011 junto a oito especialistas. Além disto, o questionário WHOQOLbref foi disponibilizado aos usuários via app, e feedbacks sobre conteúdos também são analisados e trazidos para discussão

Clotrimazole Preferentially Inhibits Human Breast Cancer Cell Proliferation, Viability and Glycolysis

BACKGROUND: Clotrimazole is an azole derivative with promising anti-cancer effects. This drug interferes with the activity of glycolytic enzymes altering their cellular distribution and inhibiting their activities. The aim of the present study was to analyze the effects of clotrimazole on the growth pattern of breast cancer cells correlating with their metabolic profiles. METHODOLOGY/PRINCIPAL FINDINGS: Three cell lines derived from human breast tissue (MCF10A, MCF-7 and MDA-MB-231) that present increasingly aggressive profiles were used. Clotrimazole induces a dose-dependent decrease in glucose uptake in all three cell lines, with K(i) values of 114.3±11.7, 77.1±7.8 and 37.8±4.2 µM for MCF10A, MCF-7 and MDA-MB-231, respectively. Furthermore, the drug also decreases intracellular ATP content and inhibits the major glycolytic enzymes, hexokinase, phosphofructokinase-1 and pyruvate kinase, especially in the highly metastatic cell line, MDA-MB-231. In this last cell lineage, clotrimazole attenuates the robust migratory response, an effect that is progressively attenuated in MCF-7 and MCF10A, respectively. Moreover, clotrimazole reduces the viability of breast cancer cells, which is more pronounced on MDA-MB-231. CONCLUSIONS/SIGNIFICANCE: Clotrimazole presents deleterious effects on two human breast cancer cell lines metabolism, growth and migration, where the most aggressive cell line is more affected by the drug. Moreover, clotrimazole presents little or no effect on a non-tumor human breast cell line. These results suggest, at least for these three cell lines studied, that the more aggressive the cell is the more effective clotrimazole is